Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
With a market cap of 141.57B, Pfizer(PFE) trades at $25.60. The stock has a price-to-earnings ratio of 15.21 and currently yields dividends of 6.6%.
On 2026-01-23, Pfizer(PFE) stock moved within a range of $25.51 to $25.79. With shares now at $25.60, the stock is trading +0.3% above its intraday low and -0.8% below the session's peak.
Trading volume for Pfizer(PFE) stock has reached 27.8M, versus its average volume of 49.61M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
PFE News
Pfizer Inc. (NYSE:PFE) CEO Albert Bourla sharply criticized Robert F. Kennedy's views on vaccines, calling them "anti-science." He suggested that meaningful pr...
Mixed options sentiment in Pfizer (PFE), with shares down 2c near $25.64. Options volume roughly in line with average with 61k contracts traded and calls leadin...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview: Pfizer is launching a new early-stage tri...
Analyst ratings
57%
of 28 ratingsMore PFE News
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview Pfizer has launched a phase 2/3 trial (NC...
Key Points Pfizer's financial results over the next few years likely won't be strong. But the drug giant's pipeline progress could help it bounce back eventua...
Key Points Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment...
Advertisement Recent performance snapshot for Pfizer (PFE) Pfizer (PFE) has moved quietly higher in recent months, with a 1-month return of 4.9% and a past 3-...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...
The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation. Pfizer (PFE +1.45%) is a high-yielding stock...
